Pfizer boosts cancer drug roster with $14 billion Medivation deal
 

Pfizer boosts cancer drug roster with $14 billion Medivation deal
(Reuters) - Pfizer Inc , beating out numerous other bidders, said it would buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.http://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...PQ:F7zBnMyn0Lo http://feeds.feedburner.com/~ff/reut...PQ:V_sGLiPBpWU
http://feeds.feedburner.com/~r/reute...~4/-xcSDg5b6ow